KR20150082109A - 토코트리에놀의 경점막 전달 - Google Patents

토코트리에놀의 경점막 전달 Download PDF

Info

Publication number
KR20150082109A
KR20150082109A KR1020147022626A KR20147022626A KR20150082109A KR 20150082109 A KR20150082109 A KR 20150082109A KR 1020147022626 A KR1020147022626 A KR 1020147022626A KR 20147022626 A KR20147022626 A KR 20147022626A KR 20150082109 A KR20150082109 A KR 20150082109A
Authority
KR
South Korea
Prior art keywords
tocotrienol
administration
tocopherol
pharmaceutical composition
sublingual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147022626A
Other languages
English (en)
Korean (ko)
Inventor
글렌 통
Original Assignee
고다겐 파마슈티컬스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by 고다겐 파마슈티컬스 피티와이 엘티디 filed Critical 고다겐 파마슈티컬스 피티와이 엘티디
Publication of KR20150082109A publication Critical patent/KR20150082109A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147022626A 2012-11-13 2013-11-13 토코트리에놀의 경점막 전달 Withdrawn KR20150082109A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AUAU2012904937 2012-11-13
AUAU2012905406 2012-12-11
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (1)

Publication Number Publication Date
KR20150082109A true KR20150082109A (ko) 2015-07-15

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147022626A Withdrawn KR20150082109A (ko) 2012-11-13 2013-11-13 토코트리에놀의 경점막 전달

Country Status (22)

Country Link
US (2) US10675265B2 (https=)
EP (1) EP2919777B1 (https=)
JP (3) JP6460998B2 (https=)
KR (1) KR20150082109A (https=)
CN (2) CN112451518B (https=)
AU (1) AU2013344817B2 (https=)
BR (1) BR112015010703B1 (https=)
CA (1) CA2891164C (https=)
DK (1) DK2919777T3 (https=)
ES (1) ES2778065T3 (https=)
IL (1) IL238727A0 (https=)
IN (1) IN2015DN04006A (https=)
MY (1) MY177940A (https=)
NZ (1) NZ628963A (https=)
PE (1) PE20151518A1 (https=)
PH (1) PH12015501048A1 (https=)
PL (1) PL2919777T3 (https=)
PT (1) PT2919777T (https=)
RU (1) RU2015120181A (https=)
SG (1) SG11201503640WA (https=)
WO (1) WO2014075135A1 (https=)
ZA (1) ZA201504191B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
CN112451518B (zh) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3933845A3 (en) 2014-10-27 2022-06-22 Aseko, Inc. Subcutaneous outpatient management
US20170128412A1 (en) * 2015-08-11 2017-05-11 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
KR20230145045A (ko) * 2020-12-04 2023-10-17 인빅터스 바이오테크놀러지 피티와이 엘티디 토코트리에놀의 경점막 전달

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) * 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP2001342133A (ja) * 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
EP1270004B1 (en) 2000-03-31 2010-06-09 Eisai R&D Management Co., Ltd. Use of gamma-tocotrienol as diuretic
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) * 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
JP4447198B2 (ja) * 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物
US6608103B2 (en) 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
EP1593127B1 (en) * 2003-02-14 2012-06-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Radiation protection by gamma-tocotrienol, alpha-tocopherol succinate or gamma-tocopherol succinate
CA2521020C (en) * 2003-04-10 2021-04-27 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
ATE491447T1 (de) * 2004-05-26 2011-01-15 Kgk Synergize Inc Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009126866A2 (en) * 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
BRPI1012170A2 (pt) 2009-05-20 2016-03-29 Lingual Consegna Pty Ltd formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.
EP2609921A1 (en) 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
US20110172312A1 (en) 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011238525A1 (en) 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
MX359670B (es) 2011-02-18 2018-10-05 Biolingus Ip Llc Proceso para preparar productos que comprenden activos estabilizados y composiciones que los comprenden.
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
CN112451518B (zh) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送

Also Published As

Publication number Publication date
EP2919777A4 (en) 2016-05-18
JP6978392B2 (ja) 2021-12-08
BR112015010703B1 (pt) 2021-02-17
CA2891164A1 (en) 2014-05-22
BR112015010703A8 (pt) 2018-08-14
US11331302B2 (en) 2022-05-17
PH12015501048A1 (en) 2015-07-27
ZA201504191B (en) 2016-11-30
US10675265B2 (en) 2020-06-09
MY177940A (en) 2020-09-28
PL2919777T3 (pl) 2020-07-13
AU2013344817B2 (en) 2015-09-17
US20150265570A1 (en) 2015-09-24
WO2014075135A1 (en) 2014-05-22
JP6460998B2 (ja) 2019-01-30
AU2013344817A1 (en) 2015-02-12
CN104582700B (zh) 2021-01-05
CN112451518B (zh) 2025-02-21
PE20151518A1 (es) 2015-11-25
EP2919777A1 (en) 2015-09-23
CA2891164C (en) 2021-02-09
EP2919777B1 (en) 2020-01-08
HK1207295A1 (en) 2016-01-29
IL238727A0 (en) 2015-06-30
ES2778065T3 (es) 2020-08-07
JP2016503407A (ja) 2016-02-04
BR112015010703A2 (pt) 2017-07-11
CN104582700A (zh) 2015-04-29
DK2919777T3 (da) 2020-03-09
PT2919777T (pt) 2020-03-30
JP2021008509A (ja) 2021-01-28
CN112451518A (zh) 2021-03-09
NZ628963A (en) 2017-02-24
SG11201503640WA (en) 2015-06-29
JP2019031504A (ja) 2019-02-28
RU2015120181A (ru) 2017-01-10
IN2015DN04006A (https=) 2015-10-02
US20200246306A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
US11331302B2 (en) Transmucosal delivery of tocotrienol
US8962594B2 (en) Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia
JP2008110996A (ja) 体脂肪低減用組成物
EP1596670A2 (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides
WO2013003689A2 (en) Compositions containing nitro fatty acids
EP4340826A1 (en) Compositions comprising mixtures of compounds and uses thereof
TWI359667B (en) Formulation for oral administration having a healt
Fatima et al. Nutraceutical and Nanonutraceutical in the Management of CVD and Hypertension
HK40048338B (zh) 生育三烯酚的经粘膜递送
HK40048338A (zh) 生育三烯酚的经粘膜递送
HK1207295B (zh) 生育三烯酚的经粘膜递送
CA3167614C (en) Nutritional compositions and methods containing a lignan and a methyl donor
EP3727359B1 (en) Treatment of fibrosis with inositol
CN116407502B (zh) 高epa含量的口服微乳及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140813

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180703

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid